Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
Thursday at 6 on WRAL: She says her Maytag oven exploded while she was asleep! How 5 On Your Side helped her out when the manufacturer wouldnât!
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
66.68
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
Next >
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
October 30, 2024
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.
Via
Benzinga
In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
October 30, 2024
Via
Benzinga
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
October 28, 2024
Via
Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
October 18, 2024
NASDAQ:BMRN is showing good growth, while it is not too expensive.
Via
Chartmill
NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals.
October 16, 2024
Investors should take notice ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
How Is The Market Feeling About Biomarin Pharmaceutical?
October 15, 2024
Via
Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...
Via
Benzinga
Analyst Expectations For Biomarin Pharmaceutical's Future
October 04, 2024
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
September 23, 2024
Via
Benzinga
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
September 26, 2024
Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability.
Via
Chartmill
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
September 25, 2024
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139...
Via
Benzinga
Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents.
September 25, 2024
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), an undervalued stock with good fundamentals.
Via
Chartmill
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%
Via
Benzinga
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
September 17, 2024
Via
Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
September 10, 2024
Via
Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
August 21, 2024
Via
Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
September 16, 2024
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits.
Via
Benzinga
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
September 16, 2024
The companies could soon face off in the growth treatment market for children with a genetic disorder.
Via
Investor's Business Daily
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Via
Benzinga
Exposures
Product Safety
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
September 05, 2024
BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth.
Via
Benzinga
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
September 05, 2024
Via
Benzinga
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
August 20, 2024
Via
Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
September 04, 2024
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...
Via
Benzinga
NASDAQ:BMRN is showing good growth, while it is not too expensive.
September 04, 2024
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced.
Via
Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
August 24, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Aug. 19-23, 2024.
Via
Talk Markets
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
August 20, 2024
Via
Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
August 14, 2024
While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable.
Via
Chartmill
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
August 07, 2024
Via
Benzinga
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
August 06, 2024
BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost reductions aim to achieve profitability by 2025. Strong Q2 performance driven...
Via
Benzinga
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
August 06, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.